Skip to main content

Advertisement

SpringerLink
Log in

Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies

  • Review Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The management of diffuse supratentorial WHO grade II glioma remains a challenge because of the infiltrative nature of the tumor, which precludes curative therapy after total or even supratotal resection. When possible, functional-guided resection is the preferred initial treatment. Total and subtotal resections correlate with increased overall survival. High-risk patients (age >40, partial resection), especially IDH-mutated and 1p19q-codeleted oligodendroglial lesions, benefit from surgery plus adjuvant chemoradiation. Under the new 2016 WHO brain tumor classification, which now incorporates molecular parameters, all diffusely infiltrating gliomas are grouped together since they share specific genetic mutations and prognostic factors. Although low-grade gliomas cannot be regarded as benign tumors, large observational studies have shown that median survival can actually be doubled if an early, aggressive, multi-stage and personalized therapy is applied, as compared to prior wait-and-see policy series. Patients need an honest long-term therapeutic strategy that should ideally anticipate neurological, cognitive and histopathologic worsening.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–25 (discussion 226–9).

    PubMed  Google Scholar 

  2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.

    PubMed  PubMed Central  Google Scholar 

  3. Rueda E, Sierra M, Infante J, Berciano J, Vázquez-Barquero A, Ciordia R, et al. Aspectos controvertidos en el manejo de gliomas hemisféricos OMS grado III: revision de la bibliografía reciente. Rev Neurol. 2011;53:747–57.

    PubMed  Google Scholar 

  4. Duffau H, Taillandier L. New concepts in the management of diffuse low-grade glioma: proposal of a multistage and individualized therapeutic approach. Neuro Oncol. 2015;17:332–42.

    CAS  PubMed  Google Scholar 

  5. Wessels PH, Weber WE, Raven G, Ramaekers FC, Hopman AH, Twijnstra A. Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol. 2003;2:395–403.

    PubMed  Google Scholar 

  6. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, et al. International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014;24:429–35.

    PubMed  Google Scholar 

  7. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.

    Google Scholar 

  8. Martino J, Taillandier L, Moritz-Gasser S, Gatignol P, Duffau H. Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas. Acta Neurochir (Wien). 2009;151:427–36 (discussion 436).

    Google Scholar 

  9. Duffau H. Contribution of cortical and subcortical electrostimulation in brain glioma surgery: methodological and functional considerations. Neurophysiol Clin. 2007;37:373–82.

    CAS  PubMed  Google Scholar 

  10. Duffau H. Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity. Lancet Neurol. 2005;4:476–86.

    PubMed  Google Scholar 

  11. Duffau H. The challenge to remove diffuse low-grade gliomas while preserving brain functions. Acta Neurochir (Wien). 2012;154:569–74.

    Google Scholar 

  12. Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within “noneloquent” areas in the left dominant hemisphere: toward a “supratotal” resection: clinical article. J Neurosurg. 2011;115:232–9.

    PubMed  Google Scholar 

  13. Duffau H. Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir (Wien). 2016;158:51–8.

    Google Scholar 

  14. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol. 2010;120:297–304.

    PubMed  PubMed Central  Google Scholar 

  15. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481–98.

    Google Scholar 

  16. Herrlinger U, Jones DT, Glas M, Hattingen E, Gramatzki D, Stuplich M, et al. Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol. 2016;131:309–19.

    CAS  PubMed  Google Scholar 

  17. Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. Acta Neuropathol. 2015;129:585–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129:867–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014;128:551–9.

    CAS  PubMed  Google Scholar 

  20. Rigau V. Histological classification. In: Duffau H, editor. Diffuse low grade glioma in adults: natural history, interaction with the brain, and new individualizad therapeutic strategies. London: Springer; 2013.

    Google Scholar 

  21. Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008;108:227–35.

    PubMed  Google Scholar 

  22. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3:159–68.

    PubMed  Google Scholar 

  23. Teixidor P, Gatignol P, Leroy M, Masuet-Aumatell C, Capelle L, Duffau H. Assessment of verbal working memory before and after surgery for low-grade glioma. J Neurooncol. 2007;81:305–13.

    PubMed  Google Scholar 

  24. Taphoorn MJ. Neurocognitive sequelae in the treatment of low-grade gliomas. Semin Oncol. 2003;30(6 Suppl 19):45–8.

    PubMed  Google Scholar 

  25. Taphoorn MJ, Schiphorst AK, Snoek FJ, Lindeboom J, Wolbers JG, Karim AB, et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol. 1994;36:48–54.

    CAS  PubMed  Google Scholar 

  26. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010;17:1124–33.

    CAS  PubMed  Google Scholar 

  27. Pallud J, Blonski M, Mandonnet E, Audureau E, Fontaine D, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol. 2013;15:595–606.

    PubMed  PubMed Central  Google Scholar 

  28. Pallud J, Mandonnet E, Duffau H, Kujas M, Guillevin R, Galanaud D, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol. 2006;60:380–3.

    PubMed  Google Scholar 

  29. Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D. Medical Research Council MESS Study Group. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet. 2005;365:2007–13.

    CAS  PubMed  Google Scholar 

  30. Leone MA, Giussani G, Nolan SJ, Marson AG, Beghi E. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. Cochrane Database Syst Rev. 2016;5:CD007144.

    Google Scholar 

  31. Duffau H, Capelle L, Lopes M, Bitar A, Sichez JP, van Effenterre R. Medically intractable epilepsy from insular low-grade gliomas: improvement after an extended lesionectomy. Acta Neurochir (Wien). 2002;144:563–72 (discussion 572–3).

    CAS  Google Scholar 

  32. Rudà R, Bello L, Duffau H, Soffietti R. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol. 2012;14(Suppl 4):iv55–64.

    PubMed  PubMed Central  Google Scholar 

  33. Piotrowski AF, Blakeley J. Clinical management of seizures in patients with low-grade glioma. Semin Radiat Oncol. 2015;25:219–24.

    PubMed  PubMed Central  Google Scholar 

  34. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6:421–30.

    PubMed  Google Scholar 

  35. Rogers LR, Morris HH, Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology. 1993;43:1599–601.

    CAS  PubMed  Google Scholar 

  36. Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947–9.

    CAS  PubMed  Google Scholar 

  37. Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol. 1998;49:436–40.

    CAS  PubMed  Google Scholar 

  38. Pallud J, Capelle L, Taillandier L, Fontaine D, Mandonnet E, Guillevin R, et al. Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro Oncol. 2009;11:176–82.

    PubMed  PubMed Central  Google Scholar 

  39. Muragaki Y, Chernov M, Maruyama T, Ochiai T, Taira T, Kubo O, et al. Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate? Minim Invasive Neurosurg. 2008;51:275–9.

    CAS  PubMed  Google Scholar 

  40. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338–45.

    PubMed  Google Scholar 

  41. McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63:700–7 (author reply 707-8).

    PubMed  Google Scholar 

  42. Claus EB, Horlacher A, Hsu L, Schwartz RB, Dello-Iacono D, Talos F, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 2005;103:1227–33.

    PubMed  Google Scholar 

  43. Ius T, Isola M, Budai R, Pauletto G, Tomasino B, Fadiga L, Skrap M. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article. J Neurosurg. 2012;117:1039–52.

    PubMed  Google Scholar 

  44. Nitta M, Muragaki Y, Maruyama T, Ikuta S, Komori T, Maebayashi K, et al. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection. Neurosurg Focus. 2015;38(1):E7.

    PubMed  Google Scholar 

  45. Duffau H, Lopes M, Arthuis F, Bitar A, Sichez JP, Van Effenterre R, et al. Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985–96) and with (1996–2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry. 2005;76:845–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Johannesen TB, Langmark F, Lote K. Progress in long-term survival in adult patients with supratentorial low-grade gliomas: a population-based study of 993 patients in whom tumors were diagnosed between 1970 and 1993. J Neurosurg. 2003;99:854–62.

    PubMed  Google Scholar 

  47. Yeh SA, Ho JT, Lui CC, Huang YJ, Hsiung CY, Huang EY. Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. Br J Radiol. 2005;78:230–5.

    PubMed  Google Scholar 

  48. Ahmadi R, Dictus C, Hartmann C, Zürn O, Edler L, Hartmann M, et al. Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients. Acta Neurochir (Wien). 2009;151:1359–65.

    Google Scholar 

  49. Schomas DA, Laack NN, Rao RD, Meyer FB, Shaw EG, O’Neill BP, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol. 2009;11:437–45.

    PubMed  PubMed Central  Google Scholar 

  50. Youland RS, Brown PD, Giannini C, Parney IF, Uhm JH, Laack NN. Adult low-grade glioma: 19-year experience at a single institution. Am J Clin Oncol. 2013;36:612–9.

    PubMed  PubMed Central  Google Scholar 

  51. Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg. 2013;118:1157–68.

    PubMed  Google Scholar 

  52. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62:753–64 (discussion 264–6).

    PubMed  Google Scholar 

  53. Duffau H, Peggy Gatignol ST, Mandonnet E, Capelle L, Taillandier L. Intraoperative subcortical stimulation mapping of language pathways in a consecutive series of 115 patients with Grade II glioma in the left dominant hemisphere. J Neurosurg. 2008;109:461–71.

    PubMed  Google Scholar 

  54. Martino J, Silva-Freitas R, Caballero H, Marco de Lucas E, García-Porrero JA, Vázquez-Barquero A. Fiber dissection and diffusion tensor imaging tractography study of the temporoparietal fiber intersection area. Neurosurgery. 2013;72(1 suppl operative):87–97 (discussion 97–8).

    PubMed  Google Scholar 

  55. Martino J, De Witt Hamer PC, Berger MS, Lawton MT, Arnold CM, de Lucas EM, et al. Analysis of the subcomponents and cortical terminations of the perisylvian superior longitudinal fasciculus: a fiber dissection and DTI tractography study. Brain Struct Funct. 2013;218:105–21.

    PubMed  Google Scholar 

  56. Alimohamadi M, Shirani M, Shariat Moharari R, Pour-Rashidi A, Ketabchi M, Khajavi M, et al. Application of awake craniotomy and intraoperative brain mapping for surgical resection of insular gliomas of the dominant hemisphere. World Neurosurg. 2016;92:151–8.

    PubMed  Google Scholar 

  57. De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 2012;30:2559–65.

    PubMed  Google Scholar 

  58. Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta Neurochir (Wien). 2012;154:575–84 (discussion 584).

    Google Scholar 

  59. Lima GL, Duffau H. Is there a risk of seizures in “preventive” awake surgery for incidental diffuse low-grade gliomas? J Neurosurg. 2015;122:1397–405.

    PubMed  Google Scholar 

  60. Duffau H. Diffuse low-grade gliomas and neuroplasticity. Diagn Interv Imaging. 2014;95:945–55.

    CAS  PubMed  Google Scholar 

  61. Duffau H. New concepts in surgery of WHO grade II gliomas: functional brain mapping, connectionism and plasticity–a review. J Neurooncol. 2006;79:77–115.

    PubMed  Google Scholar 

  62. Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810–8.

    PubMed  Google Scholar 

  63. Sarmiento JM, Venteicher AS, Patil CG. Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas. Cochrane Database Syst Rev. 2015;6:CD009229.

    PubMed Central  Google Scholar 

  64. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549–56.

    CAS  PubMed  Google Scholar 

  65. Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267–76.

    CAS  PubMed  Google Scholar 

  66. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985–90.

    PubMed  Google Scholar 

  67. Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374:1344–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Surma-aho O, Niemelä M, Vilkki J, Kouri M, Brander A, Salonen O, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology. 2001;56:1285–90.

    CAS  PubMed  Google Scholar 

  69. Gorlia T, Wu W, Wang M, Baumert BG, Mehta M, Buckner JC, et al. New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro Oncol. 2013;15:1568–79.

    PubMed  PubMed Central  Google Scholar 

  70. Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17:1521–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Reijneveld JC, Taphoorn MJ, Coens C, Bromberg JE, Mason WP, Hoang-Xuan K, et al. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17:1533–42.

    PubMed  Google Scholar 

  72. Le Rhun E, Taillibert S, Chamberlain MC. Current management of adult diffuse infiltrative low grade gliomas. Curr Neurol Neurosci Rep. 2016;16:15.

    PubMed  Google Scholar 

  73. Lassman AB. Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen CNS. Oncology. 2015;4:341–6.

    CAS  Google Scholar 

  74. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22:3133–8.

    CAS  PubMed  Google Scholar 

  75. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874–80.

    CAS  PubMed  Google Scholar 

  76. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31:337–43.

    CAS  PubMed  Google Scholar 

  77. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344–50.

    PubMed  Google Scholar 

  78. Le Rhun E, Taillibert S, Chamberlain MC. Anaplastic glioma: current treatment and management. Expert Rev Neurother. 2015;15:601–20.

    PubMed  Google Scholar 

  79. Grimm SA, Chamberlain MC. Anaplastic astrocytoma. CNS Oncol. 2016;5:145–57.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Fisher BJ, Hu C, Macdonald DR, Lesser GJ, Coons SW, Brachman DG, et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys. 2015;91:497–504.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. van den Bent MJ. Chemotherapy for low-grade glioma: when, for whom, which regimen? Curr Opin Neurol. 2015;28:633–938.

    PubMed  Google Scholar 

  82. Sloan AE, Okada H, Ryken TC, Kalkanis SN, Olson JJ. The role of emerging therapy in the management of patients with diffuse low grade glioma. J Neurooncol. 2015;125(3):631–5. doi:10.1007/s11060-015-1865-3.

    Article  CAS  PubMed  Google Scholar 

  83. Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, et al. Induction of robust type-I CD8 + T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res. 2015;21(2):286–94. doi:10.1158/1078-0432.CCR-14-1790.

    Article  CAS  PubMed  Google Scholar 

  84. DeLorenze GN, McCoy L, Tsai AL, Quesenberry CP Jr, Rice T, Il’yasova D, et al. Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma. BMC Cancer. 2010;19(10):215. doi:10.1186/1471-2407-10-215.

    Article  CAS  Google Scholar 

  85. Chaichana KL, McGirt MJ, Woodworth GF, Datoo G, Tamargo RJ, Weingart J, et al. Persistent outpatient hyperglycemia is independently associated with survival, recurrence and malignant degeneration following surgery for hemispheric low grade gliomas. Neurol Res. 2010;32(4):442–8.

    PubMed  Google Scholar 

  86. Heese O, Schmidt M, Nickel S, Berger H, Goldbrunner R, Tonn JC, et al. Complementary therapy use in patients with glioma: an observational study. Neurology. 2010;75(24):2229–35. doi:10.1212/WNL.0b013e31820202c6.

    Article  CAS  PubMed  Google Scholar 

  87. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076–84.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Neurocirugía, Hospital Universitario de Burgos, Avda Islas Baleares 3, 09006, Burgos, Spain

    P. D. Delgado-López

  2. Servicio de Oncología Radioterápica, Hospital Universitario de Burgos, Burgos, Spain

    E. M. Corrales-García & M. T. Dueñas-Polo

  3. Servicio de Neurocirugía, Hospital Universitario Marqués de Valdecilla, Santander, Spain

    J. Martino

  4. Servicio de Oncología Médica, Hospital Universitario de Burgos, Burgos, Spain

    E. Lastra-Aras

Authors
  1. P. D. Delgado-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. M. Corrales-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Lastra-Aras
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. T. Dueñas-Polo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. D. Delgado-López.

Ethics declarations

Conflict of interest

The authors report no conflict of interest regarding this manuscript.

Informed consent

Not needed for a literature review. No humans or animals participated in this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Delgado-López, P.D., Corrales-García, E.M., Martino, J. et al. Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies. Clin Transl Oncol 19, 931–944 (2017). https://doi.org/10.1007/s12094-017-1631-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-017-1631-4

Keywords

Search

Navigation